Two-Pronged gene therapy takes on deadly brain tumors
NCT ID NCT07346144
First seen Jan 17, 2026 · Last updated Jun 17, 2026 · Updated 29 times
Summary
This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack the tumor. About 68 adults aged 18-70 will receive a single injection of TGX-007 into their tumor, followed by a short course of an antiviral pill, before standard surgery. The study aims to find the safest and most effective dose and to see if it helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Hospital
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
-
Royal Infirmary of Edinburgh
RECRUITINGEdinburgh, United Kingdom
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.